TRINAMIC
7.11.2016 16:32:35 CET | Business Wire | Press release
Trinamic Motion Control GmbH & Co. KG, a leading supplier of semiconductors, electronics and mechatronic solutions in the fields of motor and motion control, is proud to announce the arrival of a new family of high-performance semiconductor components for stepper motor control. The TMC2208-LA and TMC2224-LA are monolithic components with integrated circuit breakers for up to 1.2A RMS, and optimal power controllers for noiseless, sinusoidal control of the motor phases. Above all, both components were designed with the goal of easy application in mind. Trinamic will present the drives to the public at Electronica 2016, in Hall A4 at booth 513.
"Developers are under increasing pressure to shorten development cycles and bring new products on the market faster," explains Michael Randt, founder and CEO of Trinamic. "Our new family of drivers has been specially developed to help make the development process as short and as simple as possible."
Enhanced by the flexible microPlyer interpolater unit, the components offer a resolution of up to 256 microsteps-per-full-step to achieve perfect sinusoidal control - even with low-resolution motion controllers. Further development of Trinamic's stealthChop technology, which was introduced two years ago, has all but eliminated motor noise at low speeds, making the precise control of stepper motors not only possible, but affordable for application in environments that demand absolute silence, e.g. office buildings and residential areas.
Due to the immense popularity of stealthChop technology, the components have been designed for compatibility with existing 3D printer electronics. With stealthChop there is no need for costly redesign.
Both components feature a step/direction source for fully autonomous operation. Configuration is achieved via digital inputs.
The components will be available at a price of USD 1.22 at quantities of 1000 as a QFN28 (5x5) package in the first quarter of 2017. To accelerate the design process, Trinamic offers complete end-to-end evaluation kits. The development boards are open-source hardware and freely available for use as a reference design.
About Trinamic
Trinamic, headquartered in Hamburg, provides integrated circuits and motor control modules to customers worldwide. The company's application-driven approach and in-depth understanding of their customers' needs allow them to offer solutions which simplify and shorten the design phase, resulting in significant cost savings, decreased resource allocation and a reduced total cost of ownership. Trinamic's customers benefit from the company's rich expertise in motor physics and extensive portfolio of intellectual property (IP) acquired through many years of applied experience and success. Product development at Trinamic focuses entirely on miniaturizing form factor, increasing efficiency and maximizing the safety and reliability of their products and, thereby, the systems in which they're used.
The company is fully committed to providing energy efficient solutions. Industry-leading technologies such as Trinamic's patented coolStep™ products offer user-friendliness, precise stepper motor control and, above all, energy savings.
The Trinamic Motion Control Language (TMCL) facilitates the development of motor control applications, enabling shorter development cycles and rapid product release.
Over 20 years of experience and a traditional German ownership structure with private shareholders ensure the long-term availability of their products and components.
From the headquarters in Hamburg, Germany, Trinamic products are sold via a worldwide distribution network.
Printable graphics and an English-language version of this press release are available at:
http://www.trinamic.com/company/press/
View source version on businesswire.com: http://www.businesswire.com/news/home/20161107005244/en/
Contact:
Trinamic
Jonas P. Proeger, +49 (0) 40 514 806-0
Marketing
Director
proeger@trinamic.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
